These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 26142408)
1. Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. Lehloenya RJ; Muloiwa R; Dlamini S; Gantsho N; Todd G; Dheda K J Antimicrob Chemother; 2015 Sep; 70(9):2648-51. PubMed ID: 26142408 [TBL] [Abstract][Full Text] [Related]
3. Severe cutaneous adverse reactions due to isoniazid in a HIV positive patient. Viswanath BK; Ranka P; Ramanjanayalu M Indian J Lepr; 2012; 84(3):227-32. PubMed ID: 23484337 [TBL] [Abstract][Full Text] [Related]
4. Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients. Lehloenya RJ; Wallace J; Todd G; Dheda K Int J Tuberc Lung Dis; 2012 Sep; 16(9):1260-4. PubMed ID: 22747953 [TBL] [Abstract][Full Text] [Related]
5. [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo]. Pitche P; Mouzou T; Padonou C; Tchangai-Walla K Med Trop (Mars); 2005 Sep; 65(4):359-62. PubMed ID: 16548490 [TBL] [Abstract][Full Text] [Related]
6. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. Lin YT; Chang YC; Hui RC; Yang CH; Ho HC; Hung SI; Chung WH J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):356-64. PubMed ID: 22211830 [TBL] [Abstract][Full Text] [Related]
7. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J; Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927 [TBL] [Abstract][Full Text] [Related]
8. Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. Pinho A; Coutinho I; Gameiro A; Gouveia M; Gonçalo M J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):280-287. PubMed ID: 27477905 [TBL] [Abstract][Full Text] [Related]
9. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Choon SE; Lai NM Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643 [TBL] [Abstract][Full Text] [Related]
10. Clinical features and prognostic factors in severe cutaneous drug reactions. Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402 [TBL] [Abstract][Full Text] [Related]
11. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. Barvaliya M; Sanmukhani J; Patel T; Paliwal N; Shah H; Tripathi C J Postgrad Med; 2011; 57(2):115-9. PubMed ID: 21654132 [TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601 [TBL] [Abstract][Full Text] [Related]
14. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Ding WY; Lee CK; Choon SE Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508 [TBL] [Abstract][Full Text] [Related]
16. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculosis drugs: Two case reports and a review of the literature. Coster A; Aerts O; Herman A; Marot L; Horst N; Kenyon C; Vlieghe E; Hainaut P; Baeck M Contact Dermatitis; 2019 Nov; 81(5):325-331. PubMed ID: 31021423 [TBL] [Abstract][Full Text] [Related]
17. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Teraki Y; Shibuya M; Izaki S Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse drug eruption: the role of drug patch testing. Thaiwat S; Rojanapanthu P Int J Dermatol; 2023 Jan; 62(1):108-114. PubMed ID: 36300773 [TBL] [Abstract][Full Text] [Related]